AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal

MT newswire2026/09/11 20:58

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

04:58 PM EDT, 09/11/2026 (MT Newswires) -- AstraZeneca (AZN) said Friday its late-stage trial testing Etcamah with palbociclib, a widely used breast-cancer therapy, did not meet its primary goal of improving progression-free survival. The company said it observed a numerical improvement in first-line treatment of patients with estrogen receptor-positive, HER2-negative advanced breast cancer who had not received any systemic treatment for advanced disease. The trial compared Etcamah plus palbociclib with an aromatase inhibitor plus palbociclib, AstraZeneca said. The safety profile of Etcamah in combination with palbociclib was consistent with the known safety profile of each medicine, the company said. AstraZeneca shares fell 3.3% in after-hours trading.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to Reuters on September 11, Anthropic is in talks with Nvidia, seeking to bring the chip giant onboard as a cornerstone investor for its IPO. Nvidia is reportedly considering investing up to 10 billions USD in Anthropic’s IPO. Cornerstone investors are typically institutional investors who commit to buy a certain share of the IPO before it is offered to the public, providing early endorsement for the listing.

华尔街见闻•2026/09/12 00:46